SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023

SELLAS Life Sciences Group, Inc.

2023-Q2 EPS reported -$0.77

Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.
Phase 3 REGAL (GPS) interim analysis expected late 2023/early 2024; IDMC meeting in Q3 2023.
Phase 2a SLS009 in AML dosed; topline data expected Q4 2023; Phase 1 safety completed.
Expects $13M milestone payments from 3D Medicines by end of Q3 2023.
R&D expenses $5.9M (up from $5.5M) driven by GPS and SLS009 trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2023 and providing a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001390478-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.